Generic Biologics May See Life After PDUFA; Senate Mark-Up Possible In May
Executive Summary
Leadership of the Senate Health Committee remains committed to creating a pathway for follow-on biologics, despite the fact that language was not included in an omnibus FDA bill passed out of committee April 18
You may also be interested in...
BIO’s Lucky Number 7? Follow-On Biologics Debate Offers Exclusivity Midpoint
A "split the difference" approach to determining how much exclusivity innovators would receive under a pathway establishing follow-on biologics would give brand products seven years of data exclusivity
BIO’s Lucky Number 7? Follow-On Biologics Debate Offers Exclusivity Midpoint
A "split the difference" approach to determining how much exclusivity innovators would receive under a pathway establishing follow-on biologics would give brand products seven years of data exclusivity
Follow-On Biologics Face Negotiation Slalom After Scaling Mount PDUFA
Creation of an approval pathway for follow-on biologics appears probable after proponents attached placeholder language to the user fee reauthorization bill in the Senate, but the generic industry and their allies still face considerable challenges to enacting legislation they find favorable